These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33364967)

  • 1. Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    Front Pharmacol; 2020; 11():606497. PubMed ID: 33364967
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    Clin Rheumatol; 2022 Mar; 41(3):731-739. PubMed ID: 34709497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    BioDrugs; 2020 Jun; 34(3):381-393. PubMed ID: 32078145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling.
    Zeng X; Zhang J; Yu J; Wu X; Chen Y; Wu J; Yang X; Wang J; Cao G
    Adv Clin Exp Med; 2022 May; 31(5):499-509. PubMed ID: 35148573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.
    Rudwaleit M; Claudepierre P; Kron M; Kary S; Wong R; Kupper H
    Arthritis Res Ther; 2010; 12(2):R43. PubMed ID: 20230622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
    Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
    Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis.
    Rudwaleit M; Gooch K; Michel B; Herold M; Thörner A; Wong R; Kron M; Chen N; Kupper H
    J Rheumatol; 2011 Jan; 38(1):79-86. PubMed ID: 20952469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial.
    Wei JC; Tsou HK; Leong PY; Chen CY; Huang JX
    Front Med (Lausanne); 2020; 7():566160. PubMed ID: 33195311
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study.
    Wang F; Li X; Shi Y; Zhou H; Yang G; Li R; Wu T; Liang J
    Front Pharmacol; 2023; 14():1259183. PubMed ID: 37908975
    [No Abstract]   [Full Text] [Related]  

  • 13. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
    Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
    Maksymowych WP; Rahman P; Shojania K; Olszynski WP; Thomson GT; Ballal S; Wong RL; Inman RD;
    J Rheumatol; 2008 Oct; 35(10):2030-7. PubMed ID: 18785308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
    Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.